WO2003006621A3 - Super osteocalcin promoter for the treatment of calcified tumors and tissues - Google Patents

Super osteocalcin promoter for the treatment of calcified tumors and tissues Download PDF

Info

Publication number
WO2003006621A3
WO2003006621A3 PCT/US2002/022216 US0222216W WO03006621A3 WO 2003006621 A3 WO2003006621 A3 WO 2003006621A3 US 0222216 W US0222216 W US 0222216W WO 03006621 A3 WO03006621 A3 WO 03006621A3
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
hoc
super
tissues
prostate cancer
Prior art date
Application number
PCT/US2002/022216
Other languages
French (fr)
Other versions
WO2003006621A2 (en
Inventor
Leland W K Chung
Fan Yeung
Original Assignee
Univ Virginia
Leland W K Chung
Fan Yeung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia, Leland W K Chung, Fan Yeung filed Critical Univ Virginia
Priority to AU2002354572A priority Critical patent/AU2002354572A1/en
Publication of WO2003006621A2 publication Critical patent/WO2003006621A2/en
Publication of WO2003006621A3 publication Critical patent/WO2003006621A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to an improved tissue specific promoter for gene expression and uses thereof. More particulary, the invention relates to an improved recombinant human osteocalcin (hOC) promoter that displays over 8-fold higher activity than the full-length hOC promoter and in a tissue-specific manner. In one embodiment the super hOC promoter is operably linked to a nucleic acid sequence encoding a heterologous protein, ribozyme, dominant-negative or antisense RNA for expression of those gene products in calcified tumors or bone tissues. In one embodiment hOC promoter activation by extracellular matrices and soluble factors secreted by prostate cancer and bone cells is used as a biomarker for the diagnosis and prognosis of prostate cancer.
PCT/US2002/022216 2001-07-13 2002-07-12 Super osteocalcin promoter for the treatment of calcified tumors and tissues WO2003006621A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002354572A AU2002354572A1 (en) 2001-07-13 2002-07-12 Super osteocalcin promoter for the treatment of calcified tumors and tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30536001P 2001-07-13 2001-07-13
US60/305,360 2001-07-13

Publications (2)

Publication Number Publication Date
WO2003006621A2 WO2003006621A2 (en) 2003-01-23
WO2003006621A3 true WO2003006621A3 (en) 2005-06-16

Family

ID=23180474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022216 WO2003006621A2 (en) 2001-07-13 2002-07-12 Super osteocalcin promoter for the treatment of calcified tumors and tissues

Country Status (2)

Country Link
AU (1) AU2002354572A1 (en)
WO (1) WO2003006621A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09182586A (en) * 1995-12-29 1997-07-15 S R L:Kk Recombinant vector, cell transformed thereby, and measurement of bone metabolism control activity of vitamin d derivative using the same cell
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
WO1999047177A1 (en) * 1998-03-18 1999-09-23 The University Of Virginia Patent Foundation Gene therapy vector with osteocalcin promoter and genes for bone morphogenic proteins or growth factors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09182586A (en) * 1995-12-29 1997-07-15 S R L:Kk Recombinant vector, cell transformed thereby, and measurement of bone metabolism control activity of vitamin d derivative using the same cell
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
US6159467A (en) * 1997-01-21 2000-12-12 The University Of Virginia Patent Foundation In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy
WO1999047177A1 (en) * 1998-03-18 1999-09-23 The University Of Virginia Patent Foundation Gene therapy vector with osteocalcin promoter and genes for bone morphogenic proteins or growth factors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHUNG L.W.K. ET AL.: "New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions", UROLOGY, vol. 62, no. 5, 2003, pages 44 - 54 *
DATABASE GENEMBL [online] February 2003 (2003-02-01), accession no. gencore Database accession no. M34013 *
DATABASE GENSEQ [online] April 2003 (2003-04-01), accession no. gencore Database accession no. ABZ58131 *
DATABASE GENSEQ [online] November 1997 (1997-11-01), accession no. gencore Database accession no. AAT90018 *

Also Published As

Publication number Publication date
WO2003006621A2 (en) 2003-01-23
AU2002354572A1 (en) 2003-01-29
AU2002354572A8 (en) 2009-11-17

Similar Documents

Publication Publication Date Title
Geiser et al. Characterization of the mouse transforming growth factor-β1 promoter and activation by the Ha-ras oncogene
Faure‐Vigny et al. Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO1999064594A8 (en) Genes and gene expression products that are differentially regulated in prostate cancer
WO2002062945A3 (en) Compositions and methods relating to lung specific genes and proteins
US6376661B1 (en) Human RNase H and compositions and uses thereof
US20220249346A1 (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
WO2002040672A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2003006621A3 (en) Super osteocalcin promoter for the treatment of calcified tumors and tissues
Romeo et al. Negative transcriptional regulation of the human periostin gene by YingYang-1 transcription factor
Hirano et al. Multiple transcripts of the human Cu, Zn superoxide dismutase gene
Kodama et al. Placenta growth factor is abundantly expressed in human cervical squamous cell carcinoma.
CN105400894B (en) marker for diagnosis and treatment of intervertebral disc degenerative disease
WO2004035076A1 (en) Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors
WO2002040673A3 (en) Compositions and methods relating to lung specific genes and proteins
Nagane et al. Investigation of chemoresistance-related genes mRNA expression for selecting anticancer agents in successful adjuvant chemotherapy for a case of recurrent glioblastoma.
EP3998108A1 (en) Antisense oligonucleotide capable of altering splicing of dux4 pre-mrna
MX2022011806A (en) Non-viral dna vectors and uses thereof for expressing gaucher therapeutics.
WO2004052233A3 (en) Canine rankl and methods for preparing and using the same
Li et al. Anti-angiogenesis and anticancer effects of a plasmid expressing both ENDO-VEGI151 and small interfering RNA against survivin
WO2003080105A3 (en) Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
Horiuchi et al. Cloning and characterization of a chicken platelet-derived growth factor B-chain cDNA
WO2002064788A3 (en) Compositions and methods relating to lung specific genes and proteins
Suzuki et al. Utilization of caspase-14 promoter for selective transgene expression in squamous layers of cholesteatoma in the middle ear
WO2006113973A1 (en) Transfection of collagen-producing cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP